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Abstract
Aims: To establish whether or not the state of patient oral health can influence the occurrence and/or severity of 
oral mucositis during hematopoietic progenitor cell transplantation (HPCT). 
Materials and Methods: The study included 72 patients awaiting HPCT. Prior to transplantation, clinical e�plora-
tion and radiology were carried out and oral photographs were taken. This evaluated the e�tent of caries present, 
the number of missing teeth and the number of dental fillings in each patient; CAO (Caries and Obturations Index) 
DMFS (Decayed, Missing, and Filled Surfaces) and Restoration Indices were calculated. Gingival pathology was 
also examined by means of the Ainamo and Bay Gingival Bleeding Index. O’Leary’s Plaque Index was used to 
evaluate the level of patient oral hygiene. This data was analyzed to see if it exercised any influence on the muco-
sitis grade suffered during HPCT. 
Results: 96,87% of patients suffered some degree of mucositis during their treatment by the Transplant Unit. The 
grade of mucositis was seen to be influenced by the number of missing teeth (ANOVA p<0.016) and by the DMFS 
Index (ANOVA p< 0.038). Although this was not one of the aims of this study, patient age and the administration 
of colony-stimulating factors were also seen to influence these clinical manifestations. 
Conclusions: The state of prior oral health can influence decisively the mucositis suffered during transplantation. 
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Introduction
An ageing population, the increased occurrence of cer-
tain malignant tumors and the longer survival rates of 
cancer sufferers, has lead to a significant increase in the 
numbers of patients suffering malignant neoplasias. (1).
Amongst these neoplasias, hematologic neoplasias are 
prevalent, leukemia and lymphoma being the most fre-
quent. Treatment of hematologic aplasia includes che-
motherapy (CT), radiotherapy (RT) and often a combi-
nation of both. Most of these patients will also undergo 
hematopoietic progenitor cell transplantation (HPCT) 
not only for the eradication of the cancer but also to sof-
ten the side effects of the high levels of radiation and the 
cytostatics involved in treatment. 
During the transplant period and immediately af-
terwards, patients may present a variety of symptoms, 
of which oral mucositis is one of the most frequent and 
debilitating. 
Within the field of oncology, mucositis is understood 
as the inflammation of the oral mucosa characterized 
by redness and pain, a common side effect of oncothe-
rapies. 
The occurrence of mucositis has always been e�plained 
as a combination of factors associated with and giving 
rise to this situation. These factors include: high inde� 
of epithelial buccal cell replacement, a direct effect of 
radiation and cytostatics on the tissues involved (to�i-
city), vascular disturbances that compromise healing 
processes, altered immune responses due to myelosu-
ppression and lastly, modifications to buccal flora due to 
hypoplasia and the administration of prophylactic drugs 
(antibiotics, antifungals, and antivirals).  
Several studies (2-6) suggest that various factors that 
may influence the grade of mucositis in patients un-
dergoing HPCT, although some of these have not been 
confirmed: 
- Intensity of the conditioning regime prior to HPTC. 
- Transplant type (allogeneic or autologous). 
- The origin of the cells implanted (when this is bone 
marrow mucositis is more severe than when the source 
is blood). 
- Use of colony-stimulating factors, also known as mye-
loid growth factors (the grade of mucositis appears to 
diminish, although researchers have not reached agre-
ement on this). 
- Patient age (in young patients mitotic rates are higher, 
but an increase in mucositis severity in elderly patients 
has also been observed). 
- Use of total body radiation (TBR).  
Mucositis may be caused both by radiotherapy and che-
motherapy and a combination of the two usually increa-
ses the severity of the symptoms. (7,8)
Clinical manifestations may vary, ranging from erythe-
ma or localized ulcers to the total loss of the epithelium 
with secondary hemorrhages and intense pain, which 
may give rise to (2, 9-11):
- Nutritional disturbance.
- Speaking difficulties.
- Difficulties for drug administration by mouth.
Clearly this represents a major reduction to the patient’s 
quality of life as well as increased duration of fever, 
parenteral nutrition, opiate administration and risk of 
infection, with all the related repercussions and higher 
hospitalization costs (3-5, 10). 
According to some researchers (12), oral and intestinal 
mucositis occurs in 100% of patients subjected to HPTC 
following the conditioning regime. Others (2,3,5, 7- 10, 
13,14) do not put the percentage at 100% but do state 
that it has a very high rate of incidence (Table 1). Fur-
thermore, mucositis occurs more frequently in cases of 
hematologic tumors than solid tumors (14). This is due 
to the fact that the intensity and duration of myelosu-
ppression is two or three times greater in patients with 
hemopathies and those subjected to hematopoietic pro-
genitor cell transplantation (15).
The World Health Organization established a scale of 
mucositis severity based on a number of parameters, 
which has been in use since 1979 (16). 
The WHO (17) states that buccodental health continues 
to be one of the major problems for public health the 
world over. For this reason, in 2003 the WDF, the WHO 
and the IADR, drew up a plan fixing a series of den-
tal health targets to be met in the new millennium (by 
2020) (17). Amongst these are: reduction in the death 
rate due to oral and craniofacial disease, reduction of 
the impact of oral pathologies on systemic disease and 
the integration of buccodental health care into other me-
dical disciplines. 
In accord with these last two objectives, the present stu-
dy focuses on evaluating the level of oral health in pa-
tients prior to HPCT and its influence on mucosa affec-
tation during the transplantation procedure.  
AUTHORS 
% OF MUCOSITIS 
INCIDENCE 
Spìdola and Cols. (12) 100% 
Gabriel and cols. (2) 75-99% 
Beaven and cols. (13) 98% 
Lopez Castaño and cols. (14) 40-90% 
Kostler and  cols. (7) 70% 
Blijlevens and cols. (9)   60-100% 
Sabater-Recoloms and cols. (10) 90% 
O´Brien and cols. (3)   60-100% 
Stiff, P (8) 75% 
Wardley and cols. (5) 99% 
Scully and cols. (11) 75-99% 
Table 1. Frequency of mucositis. Incidence according to differ-
ent authors.
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Objectives
The objective of this study was to discover whether the 
state of oral health (evaluated in terms of caries, gingi-
val disorders and plaque) influences the severity of oral 
mucositis during hematopoietic progenitor cell trans-
plantation.
Materials and Methods
The study included 72 patients who were due to recei-
vehematopoietic progenitor cell transplantation. They 
were referred to the Special Patients Teaching Unit at 
the University Dental Clinic by Morales Meseguer Hos-
pital Oncohematology Service. 
Oral e�ploration was performed at the University Den-
tal Clinic in morning sessions at least fifteen days be-
fore patients were to be hospitalized at the Transplant 
Unit. 
Study inclusion criteria were: 
- Patients who had been diagnosed with either cancers 
of different types and at different locations or myelo-
dysplastic syndrome.
- Treatment of these pathologies was to include hemato-
poietic progenitor cell transplantation. 
- Patients with teeth so that the state of oral health could 
be assessed; completely edentulous patients were e�clu-
ded.
Having obtained informed consent from each patient, 
clinical and radiological e�plorations were performed 
and oral photos were taken. 
The materials used for clinical e�ploration were: patient 
clinical history compiled by the Teaching Unit, an e�-
ploration kit, plaque disclosing tablets and other related 
disposable materials. Patient clinical histories were de-
signed by the Special Patients Units to meet the requi-
rements of the present study. The e�ploration kit consis-
ted of: two dental mirrors with stainless steel handles 
(Roeko®) and Nº 5 mirror (Actual®), dental tweezers 
2885 (Martin®), a 17-22 (Hu-Friedy®) e�ploratory probe 
and a PCP 11 5B (Hu-Friedy®) periodontal e�ploratory 
probe. The plaque disclosure tablets used were Plac 
Control® (Dentaid).
Radiographic e�ploration consisted of orthopantomo-
grams (OPG), which were taken before oral exploration 
began. The orthopantomography equipment used was 
the PM 2002 CC (Plamenca®).
Radiographic images necessarily included all the de-
tails to be analyzed for the purposes of the study with 
sufficient image quality for clear visualization of these 
features and structures.  
The photo camera used was a Yashica Reflex model FX-3 
fitted with a 100 mm Yashica® macro lens and three e�ten-
sion tubes, to which an annular flash was attached. Intraoral 
mirrors of various sizes and shapes were used for taking the 
photos, as well as lip separators for children and adults. 
Data collection was performed by a single practitioner 
and was recorded by a second member of the team who 
acted as au�iliary. Both the e�aminer and the data com-
piler were fully trained and all evaluations were calibra-
ted according to WHO criteria by means of the Kappa 
coefficient of determination. 
The patient was received at the dental clinic and perso-
nal details were recorded before taking the patient for 
orthopantomography (OPG). An odontogram was filled 
out which included gingival data. Oral photos were then 
taken. Lastly, each patient was given a disclosure tablet 
for evaluating the level of oral hygiene and when the 
session had come to an end the indices were calculated. 
Diagnosis of caries followed WHO criteria. Any case 
in which it was not clear whether or not these criteria 
had been met was regarded as caries-free. As well as 
registering the e�tent of caries, number of missing teeth 
and number of fillings per patient, the following indices 
were calculated: CAO (Caries and Obturations Index) 
DMFS (Decayed, Missing, and Filled Surfaces) and 
Restoration Indices. For gingival examination, gingival 
pathology was e�amined by means of the Ainamo and 
Bay Gingival Bleeding Index (simplified by Lindhe). To 
generate this index the following classifications were 
established: 
         Bleeding Intervals     Gingival Inflammation
          0%                         absent
    > 0 – 10%            slight
    > 10 – 50%             moderate
    > 50%                           severe
In addition to the Bleeding Index, an O’Leary plaque 
inde� was evaluated. This inde� was always calculated 
after photographs had been taken. This is also known as 
the Oral Hygiene Index and has the following classifica-
tions: 0-10% e�cellent; 10-25% good; 25-75% regular; 
>75% poor.
Further data was obtained from the Oncology Clinic 
medical notes taken during the transplantation pro-
cedure which included: presence or not of mucositis, 
grade of mucositis according to the WHO mucositis 
grading scale, source of hematopoietic progenitor cells 
and the administration or not of colony growth factor. 
The WHO grading scale is as follows: Grade 0: None; 
Grade 1: Soreness and/or erythema, no ulceration; Gra-
de 2: Erythema, ulcers. Patients can swallow solid diet; 
Grade 3: Ulcers, extensive erythema. Patients cannot 
swallow solid diet; Grade 4: Oral mucositis to the extent 
that alimentation is not possible.
All the data compiled was subjected to statistical analy-
sis using SPSS software. Variables were analyzed both 
descriptively and analytically. For the descriptive study, 
qualitative variables were calculated with frequency dis-
tribution, whilst for quantitative variables, means were 
calculated as a centralization measure; standard error of 
the mean and standard deviation were used as measures 
of dispersion; and ma�imums and minimums were used 
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to establish ranges. Relations between qualitative and 
quantitative variables were performed using the stu-
dent t-test whenever two averages were involved; when 
more than two were involved the analysis of variance 
test (Anova) was applied. For relationships between 
qualitative variables, contingency tables were used and 
Pearson’s chi-squared test was applied; analysis of resi-
dues was also performed where necessary. In all cases, 
a difference between groups or a relation between va-
riables was taken as statistically significant when the 
significance level was less than 0.05 (p<0.05).    
0 5 10
AML
CML
ALL
CLL
HD
NHL
MM
C. Gonadal
2ndBTM
Others
female
male
Fig. 1. Pathology distribution by gender. 2nd BMT= 2nd bone marrow transplant, C= carcinoma, MM= Multiple 
Myeloma, NHL= Non Hodgkin Lymphoma, HD= Hodgkin Disease, CLL= Chronic Lymphocytic Leukemia, 
ALL= Acute Lymphocytic Leukemia, CML= Chronic Myeloid Leukemia, AML= Acute Myeloid Leukemia.
Fig. 2. Mucositis on tongue dorsum during HPCT.
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Results
Of the 72 subjects, 42 were men and 30 were women. 
The average age of subjects was 42.2 ± 1.9 years, the 
youngest patient being 12 years old and the oldest 69. 
All subjects were due to receive HPC transplants and 
had been diagnosed with different neoplasias although 
the majority had blood dyscrasias. 37.5% of subjects 
had leukemia, 31.9% had been diagnosed with some 
type of lymphoma and 18% suffered multiple myeloma 
(Fig. 1). 
All were to undergo either autologous transplantation 
(42 subjects) or an allogeneic transplant (30 subjects). 
The majority (93.54%) were given transplants using 
progenitor cells from blood collected by means of 
aphaeresis. Only four were to be transplanted with bone 
marrow stem cells.
Only two patients did not suffer oral mucositis during 
the procedure. This meant that 96.87% did suffer some 
grade of mucositis during the period of hospitalization 
at the Transplant Unit (Fig. 2). The most frequent muco-
sitis value was grade 4 found in 64.06% of patients. In 
descending order, the second most frequent value was 
grade 3 23,43% (Fig. 3). With regard to mucositis dura-
tion, this variable was not recorded in all the case notes 
supplied by the Transplant Unit. However, this informa-
tion was made available in 52 cases, of which most fell 
within the 8 – 14 or 15 – 21 day classifications, so that 
the rest were in the <7 day class. 
65% of subjects were administered colony-stimulating 
factors whilst 35% were not. 
Initial oral health was found to be generally deficient: 
83% of patients showed caries, 67% of subjects had 
some tooth/teeth missing and 40 subjects had received 
no dental restoration treatment whatsoever (56%). The 
mean average CAO Index was 10.37 ± 0.77. Gingival 
bleeding was scarce; only 20.3% of patients showed a 
bleeding inde� greater than 50%, a value signifying a 
high level of gingival inflammation. 78.12% of the sam-
ple group showed very poor levels of oral hygiene with 
plaque accumulation on 75% of tooth surfaces. 
Evaluating the interdependence between mucositis and 
the other parameters analyzed (Table 2) it was found 
that: 
a) Mucositis/oral health relation: The grade of mucositis 
Fig. 3. Mucositis grades according WHO classification. 
Mucositis 
Grade 
Mucositis 
Duration
Sex p>0.05   p>0.05 
Age   p<0.005  p<0.005 
Growth Factors p>0.05  p<0.034 
Progenitor Source p>0.05 p>0.05 
HPCT Type  p>0.05 p>0.05 
Nº of caries p>0.05 p>0.05 
Nº of teeth lost  p<0.016 p>0.05 
Nº of obturaciones p>0.05 p>0.05 
CAO p>0.05 p>0.05 
DMFS  p<0.034 p>0.05 
Restoration Index p>0.05 p>0.05 
Plaque Index p>0.05 p>0.05 
Bleeding Index p>0.05 p>0.05 
Table 2. Factors relating to oral mucositis during HPCT. 
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suffered was seen to be influenced by the number of 
missing teeth (ANOVA p<0.016) and by the DMFS In-
dex (ANOVA p< 0.038) with patients presenting grade 2 
mucositis having more missing teeth and higher DMFS 
indices than patients with grade 3 mucositis, who in 
turn showed higher indices than patients suffering gra-
de 4 mucositis. 
b) Mucositis/periodontal health relation: The bleeding 
inde� was found to be unrelated to either the grade or 
duration of mucositis suffered during transplantation 
procedures.
c) Mucositis/oral hygiene relation: Oral hygiene was 
not found to influence mucositis.
d) Mucositis/other factors relation: The study also con-
sidered the possible dependence between mucositis and 
other factors that might exercise some influence in the 
appearance of symptoms, even though this was not a 
main study objective. Such factors included: treatment 
received prior to the transplantation procedure, the 
transplant itself, the source of hematopoietic progeni-
tor cells, the administration of myeloid growth factors 
and patient age. Transplant type was not found to in-
fluence the grade of severity or duration of mucositis 
suffered. Relating patient age with mucositis grade and 
its duration, a statistically significant relation was found 
(ANOVA p<0.005). The patient group with the youngest 
average age showed higher mucositis grades and longer 
duration. The progenitor cell source factor was not seen 
to have any influence on the grade or duration of muco-
sitis. Nor did the administration of colony-stimulating 
factors during transplantation procedure. However, a 
significant relation (Chi-squared p<0.034) was found 
with regard to the duration of mucositis symptoms, so 
that the administration of these growth factors is asso-
ciated with a reduction in the duration of mucositis. 
Discussion
Cancer is one of the major health problems the world 
over. According to the World Health Organization 
(WHO), around eleven million people are diagnosed 
with some kind of malignant tumor every year and 6.7 
million lose their lives. Of these 6.7 million, 56% are 
men and 44% are women. At present, it is estimated that 
there are 22 million people who receive medical atten-
tion for neoplasia. 
In Spain, one in three men and one in five women will 
develop some kind of cancer before the age of 74, indi-
cating that it is a very common disease. For this reason 
it is important to study and analyze all possible pro-
blems that cancer patients may suffer in all aspect of 
their lives. Knowing what these problems are is the first 
step towards solving them. 
As HPCT produces good results, it is currently used for 
treating diverse types of hematologic diseases, not only 
blood neoplasias but also certain solid tumors. For this 
reason the number of patients receiving this type of the-
rapy has risen during recent years. Given that mucositis 
is one of the most frequent side-effects of this treatment, 
and the one that causes the greatest discomfort, it is im-
portant reach an in-depth understanding of this patho-
logy in order to administer the best possible palliative 
care during HPC transplantation. 
In terms of gender, age and tumoral pathology, the stu-
dy sample was representative of patient groups in the 
literature reviewed prior to designing this study, a fact 
that facilitated comparison of our findings with those of 
other research. Concordance with the articles reviewed 
was found in terms of:  
- Se� and age of the study subjects 
- Tumoral pathology 
- The transplant type to which subjects were subjected 
- Hematopoietic progenitor cell source. 
With regard to study subjects’ oral health, a high number 
of teeth with caries was found, higher than would be e�-
pected amongst the population at large according to the 
last survey of buccodental health carried out in Spain 
in 2005; this was accompanied by a low rate of dental 
restoration. In the same way, gingival health was also 
deficient and the level of oral hygiene very poor. Fur-
thermore, the state of oral health was found to worsen 
as patient age increased. Given the presence of so many 
possible septic foci in these patients, who are highly 
susceptible to infection, it is important to recognize the 
need for and importance of providing prior dental care 
for all patients who are to be treated with HPCT. 
Regarding the analysis of mucositis grades, it is not easy 
to make comparisons across the range of research pu-
blished due to the wide variety of scales and systems for 
quantifying mucositis symptoms in use in clinical prac-
tice (14,18). Nevertheless, it would seem that increasin-
gly many researchers are adopting the scale established 
by the WHO, which is now in general use (4).
According to Wardley et al.  (5), the mucositis occurring 
in HPCT patients is usually grade 3 or 4 (64.06% and 
23.43% respectively).
Similarly, in a literature review dealing with oral mu-
cositis, Gabriel et al. (2) refer to a number of authors 
who affirm that the majority of patients suffer severe 
levels of mucositis during HPCT. In contrast to this 
review, a study carried out by Sabater-Recoloms et al. 
(10) found that the grade of mucositis most frequently 
suffered was grade 1 on the WHO scale (44,3%), and 
the more severe grades appeared in lower proportions. 
This might be due to the fact that in their study the pa-
tients were selected without distinguishing between pa-
tients who were to receive chemotherapy and those who 
were to undergo HPCT. In the present study, all patients 
underwent HPCT and so the conditioning regime was 
more intense and mucositis severity greater. 
Although there are numerous studies of the incidence 
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and intensity of mucositis during HPCT, we have been 
unable to find much research into its duration. Filicko et 
al. (4) state that it usually occurs between the second and 
eighteenth day of the transplantation procedure, whilst 
Gabriel et al. (2) place it between the third and tenth 
days. In this study, it was found that most of the subjects 
suffered mucositis between the eighth and twenty-first 
days, a finding that differs from other studies. 
In the present study, the grade of mucositis was inver-
sely related to the number of missing teeth and DMFS 
Index, in other words, the greater the number of tee-
th lost and the higher the DMFS Index, the lower the 
mucositis grade. In the case of the number of missing 
teeth, this might be due to the fact that tooth friction 
traumatizes the inflamed mucosa, given that the softer 
or more liquefied diet associated with edentulism would 
eliminate food as a traumatizing factor. 
Statistical differences were not found between plaque 
accumulation and the grade or duration of mucositis 
suffered. This contradicts the findings of other authors 
(5,10,14,15). However, there are some studies that state 
that subjecting patients to rigorous regimes of oral hy-
giene does not produce very substantial benefits with 
regard to mucositis (19). Even though many articles 
published regard oral hygiene as a conditioner for the 
development of higher or lower grades of mucositis, few 
studies have been carried out that e�amine the veracity 
of this. Given that all the patients who took part pre-
sented high plaque levels, we wonder if perhaps they 
paid little attention to oral hygiene due to their greater 
concern in the face of the much more serious systemic 
pathology that is cancer. 
A number of authors (4,6,19) affirm that the grade and 
duration of mucositis are greater in patients who re-
ceive allogeneic bone marrow transplantation (BMT) 
compared to those who receive autologous BMT. The 
findings of the present study are unable to confirm this, 
although it can be said that this is likely, given that al-
loBMT patients are subjected to a more aggressive con-
ditioning regime. In contrast to other studies reviewed 
(3,5,6), the source of hematopoietic progenitor cells was 
not found to influence mucositis.
The use of myeloid growth factors during transplan-
tation did not modify mucositis grade but was seen to 
reduce the number of days of its duration. This coinci-
des with the fact that growth factors are administered 
chiefly to reduce the days of neutropenia that the patient 
suffers following transplantation (8) and several authors 
(7,8) have inversely related neutrophil figures with the 
incidence of oral mucositis.  
However, authors have been unable to reach agreement 
as to whether the use of granulocyte colony-stimulating 
factor and granulocyte macrophage colony-stimulating 
factor benefit patients with regard to mucositis. In this 
way, whilst many authors (4, 6- 8, 11) agree on the re-
duction not only of duration but also the intensity of mu-
cositis affectation, others (5) maintain that it is counter-
productive given that its use requires more aggressive 
conditioning treatments, which can be life threatening. 
Further research is needed to find out whether myeloid 
growth factors influence the incidence, duration and 
severity of mucositis, given that some of the articles re-
viewed fail to indicate the ways in which its influence is 
e�ercised in terms of these variables. 
Mucositis severity also has an inverse relation to age 
(the younger the patient, the higher the mucositis gra-
de). It may be that younger tissues are more affected by 
oncological treatment, but nevertheless, as people tend 
to lose teeth with advancing age, this will also have an 
effect on mucositis severity as described earlier. 
With regard to mucositis duration and patient age, it 
was clear that the younger the average age, mucositis 
duration was longer. This could be due to the fact that, 
with the greater replacement of epithelial cells in young 
subjects, this may make them a more hospitable target 
for cytostatics. Many authors (7,8,10,12) include age as 
a risk factor for oral mucositis, but none of them have 
made the nature of this relation clear.  
Conclusions
In the group of patients who took part in this study, oral 
health levels were found to be poor in terms of plaque-
related diseases, with high levels of caries and teeth 
lost. Age exercises a decisive influence on the parame-
ters determining caries, so that the older the subject the 
worse the state of oral health. The Restoration Index 
was also found to be lower the older the patient. 
Both dental and gingival health were worse in this study 
group than amongst the Spanish population at large ac-
cording to the last survey of buccodental health carried 
out in Spain. 
Oral mucositis duration was seen to diminish with ad-
ministration of colony-stimulating growth factors.  Both 
the duration and grade of mucositis increased as patient 
age got younger.  
The higher the number of missing teeth and the higher 
the DMFS Index, the lower the grade of oral mucositis 
suffered during HPCT. 
Oncohematological Services should work more closely 
with dental services in order to reduce, as far as pos-
sible, mucosa complications during HPCT, so that pa-
tients enter the Transplant Unit in a better state of oral 
health.  
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